Blazar

Blazar redefines pre-clinical R&D with cutting edge AI, turning clinical data into faster breakthroughs. From biomarker discovery to seamless workflows, we are reinventing innovation in healthcare.

Blazar’s AI platform, currently at TRL 5, is transforming pre-clinical R&D by bridging lab validation with real-world applications. Our technology has demonstrated a 20% improvement in patient grouping for oncology and has the potential to cut biomarker discovery timelines by 40%, bringing life-changing treatments closer to patients faster. With collaborations in place with biopharma and research institutions, we’re already proving how our platform streamlines workflows and unlocks powerful insights, making biomedical innovation more efficient and impactful.

Pre-clinical R&D faces inefficiencies in integrating clinical data for precision reporting and biomarker discovery, with siloed workflows slowing innovation and increasing costs. Over 90% of oncology trials fail due to poor biomarker and patient selection, leading to suboptimal therapies, wasted resources, and reduced patient well-being. Blazar’s AI platform bridges these gaps by streamlining workflows, delivering actionable insights, and accelerating R&D, driving faster, better healthcare innovation.

Blazar’s AI platform revolutionizes biomedical research by bridging clinical and pre-clinical data, enabling actionable insights from multi-omics and trial data. Unlike siloed methods, it integrates datasets into intuitive workflows, streamlining precision reporting and biomarker discovery. Scalable and compliance-ready, Blazar adapts to R&D needs, optimizing decision-making, reducing inefficiencies, and accelerating breakthroughs. With Blazar, pre-clinical R&D becomes faster, smarter, and impactful.

Blazar operates on a scalable SaaS model designed to meet the unique needs of biomedical R&D centers, offering flexible licensing tiers that make our platform accessible to a wide range of organizations. We also provide high-value consulting services, working closely with partners to build custom AI solutions that seamlessly integrate clinical data into their research pipelines. This dual-revenue approach allows us to be more than just a product—we become a trusted partner in driving innovation and accelerating breakthroughs in biomedical research.

Startup Accelerators:
2022 - P4 Precision Medicine Accelerator Remote UK
2021 - TEKNE Paris
2020 - TechCare Paris and Female Founders Austria
2019 - Entrepreneur First Paris